ESTROGEN RECEPTOR AGONISTS
Faslodex is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat estrogen receptor-positive breast cancer in postmenopausal women whose cancer progressed after treatment with antiestrogen therapy such as tamoxifen. Faslodex is also known by its drug name, fulvestrant.
About two-thirds of breast cancers are estrogen receptor-positive, meaning that they require estrogen in order to grow. Faslodex is a member of a class of drugs called estrogen receptor agonists. Faslodex is believed to work by blocking estrogen from acting on breast cancer cells, thereby slowing the growth of the cancer.
How do I take it?
Faslodex is taken as an intramuscular injection administered in a clinical setting. When you begin taking Faslodex, you will need to receive three injections in the first month as a loading dose. After the first month, Faslodex is taken once a month. Each dose consists of two injections, one in each buttock.
You may need to take Faslodex for several years.
Common side effects of Faslodex include injection site pain, nausea, bone pain, joint pain, headache, back pain, fatigue, pain in the extremities, hot flashes, vomiting, decreased appetite, weakness, musculoskeletal pain, cough, indigestion, and constipation.
Serious side effects of Faslodex include fetal harm in pregnant people, bleeding disorders, and liver impairment.
For more information about this treatment, visit:
Faslodex — BreastCancer.org
Faslodex — RxList